ORAL DOSAGE FORM OF TETRAHYDROCANNABINOL AND A METHOD OF AVOIDING AND/OR SUPPRESSING HEPATIC FIRST PASS METABOLISM VIA TARGETED CHYLOMICRON/LIPOPROTEIN DELIVERY
An oral dosage form of cannabinoids and/or standardized marijuana extracts in a self-emulsifying system operable to avoid hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery for promoting lymphatic transport. The oral dosage form includes: (a) a pharmacologically active form of cannabinoids and/or standardized marijuana extracts and (b) an oily medium consisting of: (i) about 15 to 85 wt % of one or more triglycerides formed from long chain fatty having from C13 to C24 carbon atoms (ii) about 15 to 85 wt % of one or more mixed glycerides formed from long chain fatty having from C13 to C24 carbon atoms and (iii) one or more free fatty acids formed from un-esterified long chain fatty acids having from C13 to C24 carbon atoms and (c) about 10 to 70 wt % of a surfactant which promotes self-emulsification.
